Jazz Pharmaceuticals has delivered a very strong 1 year share price gain, yet the valuation checks still flag the stock as looking cheap rather than fully priced. For investors, that mix of past returns and a high value score raises questions about how much of the recent good news is already reflected in Jazz Pharmaceuticals' current US$240.07 share price.
- Over the past 12 months, Jazz Pharmaceuticals has returned 89.2%, which puts recent enthusiasm for the stock front and center for anyone thinking about new money going in.
- Positive trial results for the HER2 targeted cancer therapy Ziihera and fresh regulatory milestones can support higher earnings expectations, while the decision to fund growth with US$1.1b in exchangeable notes introduces balance sheet and dilution risk that investors need to factor into any valuation work.
- On Simply Wall St's broader checks, Jazz Pharmaceuticals earns a high value score of 5 out of 6, which means the stock currently screens as undervalued on most conventional measures rather than expensive after its rally.
The issue now is whether Jazz Pharmaceuticals' strong share price performance still leaves a meaningful valuation cushion, or whether the easy money on this story has already been made.
Spot opportunities beyond Jazz Pharmaceuticals by scanning a curated list of 49 high quality undervalued stocks with similar value scores and strong recent share price momentum.Does Jazz Pharmaceuticals Look Undervalued on Earnings?
The P/E ratio is a good fit for Jazz Pharmaceuticals because earnings remain a key anchor for how investors frame the business today. On this basis, the stock trades at about 16.6x current earnings. The broader pharmaceuticals group sits around 16.2x, which puts Jazz Pharmaceuticals almost level with the sector at first glance.
The fair P/E multiple implied by Simply Wall St’s model is higher at roughly 24.8x, based on the company’s risk profile, profitability and size. That is a sizeable gap to the current 16.6x, indicating a discount rather than a premium. Despite the share price reaction to positive Ziihera trial news and regulatory progress, the earnings multiple still prices Jazz Pharmaceuticals below both the fair ratio and the peer average of about 35.8x.
On a P/E basis, Jazz Pharmaceuticals currently appears undervalued relative to what the model suggests investors might typically be willing to pay for its earnings.
See what the numbers say about this price — find out in our valuation breakdown.
The Jazz Pharmaceuticals Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Jazz Pharmaceuticals pick up where the valuation debate leaves off and explain the specific paths for revenue, margins and earnings that would need to occur for Jazz Pharmaceuticals' share price to sit meaningfully above or below where it is today on the screen. Rather than relying on a single model output, these scenarios unpack the assumptions behind any fair value figure so you can monitor whether that future is actually unfolding.
Community views on Jazz Pharmaceuticals are sharply split, with one camp leaning into the oncology buildout and another fixated on patent and pricing risk.
Bull case: 17% undervalued
"Bullish analysts see Ziihera as a central growth pillar, with the new US$3b to US$5b peak sales range cited as a core reason to lift price targets and assign higher long term contribution to Jazz Pharmaceuticals' oncology segment..."
Read the full Bull Case to see why Jazz Pharmaceuticals could be undervalued
Bear case: 13% overvalued
"The anticipated entry of generic competition for high sodium oxybate products by year-end 2025, combined with possible expiry of AG agreements before 2027, could significantly erode Jazz's oxybate franchise revenues and reduce net margins over time..."
Read the full Bear Case to see why Jazz Pharmaceuticals could be overvalued
Do you think there's more to the story for Jazz Pharmaceuticals? Head over to our Community to see what others are saying!
The Bottom Line
For Jazz Pharmaceuticals, the current P/E discount suggests the market is still pricing in a fair amount of caution despite recent progress on oncology and regulatory fronts. The broader valuation checks lean toward undervalued, yet the balance sheet impact of the exchangeable notes and the risks to the oxybate franchise prevent this from appearing to be a simple multiple re rating story. The key variable from here is whether future earnings from Ziihera and the wider oncology effort can offset potential pressure on legacy products sufficiently to persuade investors that the current discount reflects opportunity rather than a value trap.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com